Description

CAGRILINTIDE – ADVANCED METABOLIC & APPETITE SUPPORT

Elevate Wellness Hub’s Cagrilintide is an investigational long-acting amylin analogue being studied for its role in appetite regulation, food intake, body-weight management, and metabolic health. Cagrilintide is also being investigated in combination with semaglutide as CagriSema.

KEY BENEFITS

• Supports research into appetite and food-intake regulation

• Investigated for body-weight management

• Supports research into metabolic health

• Investigated for longer-term weight-management strategies

• Supports research into satiety and eating behaviour

• Being studied both independently and in combination with semaglutide

WHO MAY BENEFIT?

Cagrilintide is currently an investigational medicine being studied primarily in adults with overweight or obesity, including people with and without type 2 diabetes. It is not currently an approved general-use treatment, and eligibility for clinical use should be determined by a qualified healthcare professional or appropriate clinical-trial setting.

Always use under the guidance of a qualified healthcare professional.

HOW IT MAY HELP

• Acts on amylin-related pathways involved in appetite and satiety

• Is being investigated for its ability to reduce food intake

• Supports research into sustained appetite control and weight management

• May complement other metabolic pathways when investigated alongside GLP-1 medicines

• Clinical studies have demonstrated meaningful reductions in body weight in studied populations, while safety and efficacy continue to be evaluated in Phase 3 development.

POSSIBLE SIDE EFFECTS

Clinical studies have reported gastrointestinal adverse effects, which may include:

• Nausea

• Diarrhea

• Constipation

• Vomiting

• Abdominal discomfort

• Reduced appetite

• Other gastrointestinal symptoms

In a Phase 3 study of cagrilintide 2.4 mg, gastrointestinal adverse events were reported relatively frequently, with nausea, constipation, diarrhea, and vomiting among the reported events.

Because cagrilintide remains investigational, its complete long-term safety profile has not yet been established.

NOT SUITABLE FOR

• Pregnancy or breastfeeding

• Anyone with a known allergy or sensitivity to the ingredients

• Children unless specifically directed by an appropriate specialist or within an authorised clinical-trial setting

• Individuals with significant medical conditions without appropriate healthcare supervision

• Anyone using other appetite-regulating, weight-management, or glucose-lowering medicines without professional medical guidance

• Anyone seeking to substitute an investigational product for an approved medical treatment

IMPORTANT DISCLAIMER

Cagrilintide is an investigational medicine and is not currently approved for general public use. It remains under clinical investigation, including Phase 3 studies. Cagrilintide is also being studied as part of CagriSema, a combination of cagrilintide and semaglutide.

Elevate Wellness Hub does not represent Cagrilintide as an approved treatment or as a substitute for approved medical therapy. Any use must comply with applicable laws and regulations and should occur only under appropriate qualified healthcare-professional supervision or within an authorised clinical-trial setting.

The 10 mg listed on the Elevate Wellness Hub product list refers to the product strength and is not a dosing recommendation.

It’s not just about feeling better, it’s about elevating your quality of life.

ELEVATE WELLNESS HUB – PEPTIDE WELLNESS – SCIENCE BACKED. RESULTS DRIVEN. YOU ELEVATED.